Columbus OH 膀胱癌临床试验
19项针对 膀胱癌的研究正在 Columbus及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- 以及另外 11 项
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
招募中2 期
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- Doctors Hospital, Columbus
- 以及另外 1 项
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- 以及另外 8 项
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
招募中1 期
- The Ohio State University (OSU), Columbus
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
招募中3 期
- Ohio State University Comprehensive Cancer Center, Columbus
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
招募中观察性研究
- The Ohio State University, Columbus
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
招募中3 期
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
招募中3 期
- Ohio State University Comprehensive Cancer Center, Columbus
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
招募中2 期
- Ohio State University Comprehensive Cancer Center, Columbus
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
招募中1 期
- Ohio State University, Columbus
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
招募中2 期
- Ohio State University, Columbus
- Central Ohio Urology Group (US Urology Partners), Gahanna · 距离 7 英里
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
招募中1/2 期
- The Ohio State University Comprehensive Cancer Center, Columbus
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
招募中1/2 期
- Central Ohio Urology Group, Gahanna · 距离 7 英里
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
招募中2/3 期
- The James Outpatient Care West Campus, Columbus
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
招募中2 期
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
招募中2 期
- Ohio State University Hospital, Columbus
- Ohio State University, Columbus
- OSU Wexner Medical Center & James Cancer Hospital, Columbus
- 以及另外 2 项
Blue Light Cystoscopy With Cysview® Registry
招募中观察性研究
- Ohio State University Wexner Medical Center, Columbus
- Ohio State University, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Columbus
其他城市的 膀胱癌试验
- New York City, NY36 项研究
- Nashville, TN31 项研究
- Houston, TX31 项研究
- Dallas, TX27 项研究
- Boston, MA26 项研究
- Washington, DC26 项研究
- Los Angeles, CA25 项研究
- Baltimore, MD24 项研究
- Philadelphia, PA23 项研究
- Edison, NJ23 项研究
- St. Louis, MO22 项研究
- Chicago, IL21 项研究
Columbus的其他研究
- 非小细胞肺癌57 项研究
- 癌症（所有类型）40 项研究
- 乳腺癌39 项研究
- 卵巢癌39 项研究
- 肺癌36 项研究
- 急性髓系白血病34 项研究
- 慢性淋巴细胞白血病29 项研究
- 转移性癌症25 项研究
- 多发性骨髓瘤25 项研究
- 前列腺癌25 项研究
- 子宫内膜癌24 项研究
- 结直肠癌24 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。